1 Jun 2011 10:27
For immediate release | 1 June 2011 |
ABCAM PLC
("Abcam" or "the Company")
Total Voting Rights - Voting Rights and Capital
In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 181,720,797 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.The above figure of 181,720,797 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
Date of Notification: 1 June 2011
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer www.abcamplc.com | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality research-grade antibodies and associated proteomics research products. Antibodies and related products are essential tools for life scientists enabling them to analyse components of living cells at the molecular level.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Cambridge, Massachusetts (USA), Tokyo (Japan) and Hong Kong (China) allowing them to serve a global customer base of 75 countries. Abcam employs over 290 staff across its four operating companies.
Abcam now has an online catalogue of over 72,000 products sourced from over 250 suppliers. The catalogue includes a growing range of non-antibody products such as proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research and detection tools globally.